Alamar Biosciences, Inc. current report, 15 July 2026

Alamar Biosciences, Inc. — Form 8-K

Filed: July 15, 2026. The report concerns a board change, not a financial reporting period.

Business context and board changes

Independent director Ian Ratcliffe, who had served since February 2024, passed away on July 5, 2026. The company expressed condolences and appreciation for his service. Following his passing, the Board reduced the authorized number of directors to five and appointed Nicholas Naclerio, Ph.D., to the Audit Committee.

Financial information

This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial results.

Outlook, risks, and contingencies

The filing provides no financial guidance or outlook and identifies no new risks, contingencies, or unusual financial items.

Key facts to verify

  • Confirm the Board’s current composition and authorized size of five directors.
  • Confirm the Audit Committee’s composition following Dr. Naclerio’s appointment.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.